FDA approves Retatrutide this year priced at 9.8% on Polymarket, up 6.6 points, on $597K traded

Polymarket traders put the probability of FDA approval for Retatrutide this year at 9.8%, up 6.6 percentage points, with $597K traded, according to the supplied market update published Oct 29, 2026, at 3:09 PM ET. Despite the increase, the market continued to assign a low probability to approval before year-end.

A price move without a documented catalyst

The supplied news summary reported no significant new platform headline in the preceding 30 minutes. It said searches had resurfaced previously handled material, but provided no Retatrutide-specific development explaining the repricing.

That leaves a distinction between the observed trading move and the underlying regulatory outlook. The material establishes a change in market pricing, not a new FDA decision or an update to an approval timetable.

Reading the market data

According to PredictionBubbles, its market-data pages refresh every 15 minutes, while trading on the underlying venues continues between updates. The site defines probability changes as percentage-point moves over the previous 24 hours and reports total traded volume separately.

The supplied PredictionBubbles page describes its tracking methodology but does not include a Retatrutide-specific listing, price history or resolution terms. The headline figures therefore cannot be independently checked against that excerpt, and the exact conditions required for this contract to settle are not provided.

What it means for prediction markets

• The repricing is not confirmation: A 9.8% implied probability still places approval this year well below an even chance.
• Volume and fresh buying are different: The $597K figure represents reported traded volume, not necessarily money exchanged during the latest move.
• The catalyst remains unverified: No Retatrutide-specific news in the supplied material accounts for the 6.6-point increase.
• Settlement details matter: Without the contract’s wording and resolution rules, the precise approval event and deadline cannot be assessed.